

March 24, 2025

Subject: Invitation to the Annual General Meeting of Shareholders 2025

To: Shareholders of Bangkok Genomics Innovation Public Company Limited

Enclosures

1. Minutes of the Annual General Meeting of Shareholders 2024
2. Articles of Association of the Company concerning shareholders' meetings
3. Profile of independent directors for proxy cases
4. Profile of candidates nominated for election as directors of the Company
5. Information for appointment of the Company's independent auditor and Profile of auditor
6. Procedures, Registration Method, and Guidelines for Attending the 2025 Annual General Meeting of Shareholders via Electronic Media
7. Required Documents and Evidence for Identity Verification to Confirm the Right to Attend the Shareholders' Meeting
8. Proxy Forms A, B, and C (Proxy Form B is recommended)
9. 56-1 One Report in QR Code
10. Privacy Notice for the Company's Annual General Meeting of Shareholders 2025

The Board of Directors of Bangkok Genomics Innovation Public Company Limited (the “**Company**”) No.1/2025 has resolved to convene the Annual General Meeting of Shareholders 2025 on April 28, 2025 at 10:30 AM via electronic means only (E-AGM) in accordance with the relevant laws and regulations governing electronic meetings. The Company has determined 14 March 2025 to be the record date for determining the list of shareholders entitled to attend the Annual General Meeting of Shareholders (Record Date).

The Company therefore gives notice of the meeting agenda according to the resolutions of the Board of Directors as follows:

Agenda Item 1 Chairman's Report

Objective and Reason: This agenda item allows the Chairman to independently address any matters of interest that shareholders should be informed about.

The Board of Directors' Opinion: For acknowledgment.

Required Vote: This agenda item is for acknowledgement and there will be no casting of votes.

Agenda Item 2 To consider and adopt the minutes of the Annual General Meeting of Shareholders 2024

Objective and Reason: The Company held the Annual General Meeting of Shareholders 2024 on February 29, 2024, a copy of which is enclosed herewith as Enclosure 1.

The Board of Directors' Opinion: The Board of Directors has reviewed the minutes and confirmed that they were accurately and completely recorded in accordance with the resolutions passed by the shareholders during the meeting. The Board recommends that the shareholders approve the minutes of the 2024 Annual General Meeting of Shareholders, held on February 29, 2024, as an official and accurate record of the Company's proceedings.

Required Vote: This agenda item must be approved by a majority vote of the shareholders present at the Meeting and casting their votes.

Agenda Item 3 To acknowledge the reports of board of directors and operating results for the year ended 31 December 2024

Objective and Reason: The Company's operating results for the fiscal year 2024 are presented in the 2024 Annual Report (Form 56-1 One Report), as detailed in Enclosure 8.

The Board of Directors' Opinion: Deems it appropriate to propose that the Annual General Meeting of Shareholders acknowledge the Company's operating results for the year 2024.

Required Vote: This agenda item is for acknowledgement and there will be no casting of votes.

Agenda Item 4 To consider and approve the financial statements for the year ended 31 December 2024

Objective and Reason: In accordance with Section 112 of the Public Limited Companies Act B.E. 2535 (1992) (including amendments) and Article 55 of the Company's Articles of Association, the Board of Directors is required to prepare a balance sheet and a statement of profit and loss as of the end of the fiscal year and submit them for approval at the Annual General Meeting of Shareholders. The Board of Directors must ensure that the financial statements are audited by the auditor prior to submission to the shareholders' meeting. In this regard, the Company has prepared the financial statements for the fiscal year ended December 31, 2024. The details are provided in Section 3: Financial Statements of the 2024 Annual Report (Form 56-1 One Report), as detailed in Enclosure 8. A summary of the key financial highlights is as follows:

(Unit: Million Baht)

Items	Consolidated Financial Statements	Separate Financial Statements	
	2024 (Proposed Year)	2024 (Proposed Year)	2023
Total Assets	607.59	605.75	293.02
Total Liabilities	68.44	68.40	57.20
Shareholders' Equity	539.15	537.35	235.82
Paid-up Capital	300.00	300.00	220.00
Total Revenue	337.59	337.59	245.39
Net Profit	50.16	50.32	32.14
Basic Earnings Per Share (Baht/Share)	0.09	0.09	0.07

The Board of Directors' Opinion: Deems it appropriate to propose that the Annual General Meeting of Shareholders for consideration and approval of the Company's financial statements for the year ended December 31, 2024. These financial statements have been audited and certified by the Company's auditor, Dr. Virach & Associates Office Co., Ltd. They have also been reviewed by the Audit Committee and approved by the Board of Directors at its meeting on February 26, 2025.

Required Vote: This agenda item must be approved by a majority vote of the shareholders present at the Meeting and casting their votes.

Agenda Item 5 To consider and approve the allocation of the net profit as a legal reserve and dividend payment

Objective and Reason:

1. In accordance with Section 116 of the Public Limited Companies Act and Article 50 of the Company's Articles of Association, the Company is required to allocate a portion of its annual net profit as a legal reserve, at a rate of no less than 5% of the annual net profit, after deducting any accumulated losses carried forward (if any), until the reserve reaches at least 10% of the registered capital.
2. The Company has a dividend policy to distribute dividends to shareholders at a rate of no less than 40% of the net profit from the Company's separate financial statements, after deducting corporate income tax and allocating the required legal reserve. However, the Company may consider paying dividends at a different rate from the stated policy, depending on its operating performance, financial position, liquidity, working capital requirements, business expansion plans, and overall economic conditions.
3. The dividend payment information based on the operating results for the year 2024 is as follows:

Details of Dividend Payment	2024 (Proposed Year)	2023
Net profit from separate financial statements (Baht)	50,318,711	32,141,734
Number of shared (shares)	600,000,000	440,000,000
Legal Reserve as of December 31 (Baht)	11,000,000	8,460,000
Dividend Payment Rate (Baht/Share)	0.05	0.0545
Total Dividend Payment (Baht)	30,000,000	24,000,000
Dividend Payout Ratio to Net Profit (%)	59.62	74.67

The Board of Directors' Opinion: The Board of Directors has considered various factors, such as the Company's operating performance and dividend payment policy, and deems it appropriate to propose for consideration at the Annual General Meeting of Shareholders as follows:

- (1) Approve the allocation of net profit as a legal reserve for the year 2024, in the amount of 2,540,000 Baht, which is not less than 5% of the Company's net profit.
- (2) Approve the dividend payment for the 2024 operating results at a rate of 0.05 Baht per share, totaling 30,000,000 Baht.

In this regard, the Company has set the Record Date to determine shareholders entitled to receive the dividend on May 7, 2025, and the dividend payment date on May 28, 2025. However, the right to receive the dividend remains uncertain, as it is subject to approval by the 2025 Annual General Meeting of Shareholders.

Required Vote: This agenda item must be approved by a majority vote of the shareholders present at the Meeting and casting their votes.

Agenda Item 6 To consider and approve the appointment of directors in replacement of those who must retire by rotation

Objective and Reason: In accordance with Section 71 of the Public Limited Companies Act and Article 18 of the Company's Articles of Association, at every Annual General Meeting of Shareholders, one-third (1/3) of the directors, or if it is not a multiple of three, then the number nearest to one-third (1/3) must retire from office. There must be a drawing by lots to determine the directors retiring on the first and second years following the registration of the Company. In each subsequent year, the directors who occupy the position for the longest period must retire. A retiring director is eligible for re-election. Currently, the Company has a total of 11 directors. At the Annual General Meeting of Shareholders 2025, the three directors due to retire by rotation are as follows:

1. Mr.Vichate Tantiwanich Independent Director / Chairman of the Audit Committee
2. Mr.Jedsada Chokdamsongsuk Independent Director / Audit Committee
3. Mr.Zoongze Wu Director

The Board of Directors' Opinion: The Board of Directors, excluding those with a conflict of interest, deems it appropriate to propose to the Annual General Meeting of Shareholders 2025 to re-elect the three directors who are due to retire by rotation, namely: Mr. Vichate Tantiwanich, Mr. Jedsada Chokdamsongsuk, and Mr. Zongze Wu for another term as directors of the Company.

Required Vote: This agenda item must be approved by a majority vote of the shareholders present at the Meeting and casting their votes.

Agenda Item 7 To consider and approve the directors' remuneration for the year 2025

Objective and Reason: In accordance with Section 90 of the Public Limited Companies Act, the remuneration of directors must comply with the Company's Articles of Association and be approved by a resolution of the shareholders' meeting, with a vote of not less than two-thirds (2/3) of the total votes of the shareholders present at the meeting. Additionally, Article 33 of the Company's Articles of Association states that directors are entitled to receive compensation from the Company in the form of rewards, meeting allowances, gratuities, bonuses, or other benefits as determined by the shareholders' meeting. The compensation may be fixed as a specific amount, set as a guideline, or established as an ongoing policy until further changes are made. Directors are also entitled to allowances and other benefits in accordance with the Company's regulations.

The Board of Directors, after careful consideration by the Executive Committee, has evaluated the principles for determining the remuneration of the Company's directors by scrutinizing the appropriateness of the remuneration to be in the same way as listed companies in the same industry as well as considering the operating results, business size, responsibilities of the Board of Directors and the Company's net profit. Therefore, it is deemed appropriate to propose maintaining the director compensation at the same level as in 2024, as detailed below:

Monthly Remuneration of the Board of Directors (Baht/person)

Position	2025 (Proposed Year)	2024
Chairman of the Board	50,000	50,000
Directors	40,000	40,000

Meeting Allowance for Sub-committees. (Audit Committee and Executive Committee)

(Baht/person/time)

Position	2025 (Proposed Year)	2024
Chairman of the Board	20,000	20,000
Directors	15,000	15,000

Furthermore, directors who hold executive positions in the Company will receive compensation solely in their capacity as executives and will not receive any compensation in their capacity as directors. (Chief Executive Officer and Deputy Chief Executive Officer)

The Board of Directors' Opinion: It is deemed appropriate to propose that the Annual General Meeting of Shareholders consider and approve the remuneration for the Board of Directors and Sub-committees for the year 2025, including monthly remuneration and meeting allowances, at the same level as in 2024.

Required Vote: This agenda item must be approved by a vote of not less than two-thirds of the total number of votes of the shareholders attending the meeting.

Agenda Item 8 To consider and approve the payment of bonuses to the executive directors for the year 2024

Objective and Reason: In accordance with Section 90 of the Public Limited Companies Act, the remuneration of directors must comply with the Company's Articles of Association and be approved by a resolution of the shareholders' meeting, with a vote of not less than two-thirds (2/3) of the total votes of the shareholders present at the meeting. Additionally, Article 33 of the Company's Articles of Association states that directors are entitled to receive compensation from the Company in the form of rewards, meeting allowances, gratuities, bonuses, or other benefits as determined by the shareholders' meeting. The compensation may be fixed as a specific amount, set as a guideline, or established as an ongoing policy until further changes are made. Directors are also entitled to allowances and other benefits in accordance with the Company's regulations.

The Board of Directors has reviewed the Company's operating performance, business size, and net profit, which are the results of the effective management and leadership of the Executive Committee.

The Board of Directors' Opinion: It is deemed appropriate to propose to the Annual General Meeting of Shareholders for consideration and approval of the payment of bonuses to the Executive Committee for the 2024 operating results, at a rate of 5% of the net profit, amounting to 2,500,000 Baht.

Furthermore, directors who hold executive positions in the Company will receive compensation solely in their capacity as executives and will not receive any compensation in their capacity as directors. (Chief Executive Officer and Deputy Chief Executive Officer)

Required Vote: This agenda item must be approved by a vote of not less than two-thirds of the total number of votes of the shareholders attending the meeting.

Agenda Item 9 To consider and approve the appointment of auditor and fix his/her remuneration for the year 2025

Objective and Reason: In accordance with Section 120 of the Public Limited Companies Act and Articles 58 and 59 of the Company's Articles of Association, the Annual General Meeting of Shareholders is required to appoint the Company's auditor and determine the audit fee annually.

The Audit Committee has considered and selected Dr. Virach & Associates Office Co., Ltd. as the Company's audit firm for the year 2025. This selection is based on the firm's approval by the Securities

and Exchange Commission (SEC), maintains internationally recognized auditing standards, and has demonstrated expertise in auditing with consistent efficiency, quality, and reliability. The firm has performed well in past audits, ensuring timely and credible financial reviews. Additionally, a comparison of work volume and audit fees with similar firms confirms that Dr. Virach & Associates Office Co., Ltd. offers reasonable audit fees.

The names of the auditors who will express an opinion on the Company's financial statements and sign the financial reports, along with other relevant details, are provided in Enclosure 4.

The Board of Directors' Opinion: The Board of Directors concurs with the Audit Committee's recommendation and proposes to the Annual General Meeting of Shareholders 2025 to appoint Dr. Virach Aphimeteetamrong (Certified Public Accountant No. 1378), Mr. Chaiyakorn Aunpitipongsa (Certified Public Accountant No. 3196), or Mr. Apiruk Ati-anuwat (Certified Public Accountant No. 5202) of Dr. Virach & Associates Office Co., Ltd. as the Company's auditors for 2025.

The audit firm and the nominated auditors have no relationships or conflicts of interest with the Company, its executives, major shareholders, or related persons.

Additionally, the Board deems it appropriate to propose that the Annual General Meeting of Shareholders approve the audit fee for 2025 in the amount of 1,830,000 Baht, covering the annual financial statement audit, quarterly financial statement audits, investment promotion certificate audit, consolidated annual financial statement audit, and consolidated quarterly financial statement audits. However, this audit fee does not include non-audit service fees.

Required Vote: This agenda item must be approved by a majority vote of the shareholders present at the Meeting and casting their votes.

Agenda Item 10 Other matters (If any)

The Company provides an opportunity for shareholders to submit questions related to the 2025 Annual General Meeting agenda or any other important company information in advance via email at BKGI_IR@bangkokgenomics.com. This allows the Board of Directors or management to prepare responses accordingly.

The Company cordially invites shareholders to attend the 2025 Annual General Meeting of Shareholders on April 28, 2025, at 10:30 AM, which will be held exclusively via electronic means (E-AGM) in compliance with relevant laws governing electronic meetings. Shareholders can review the registration procedures, proxy appointment process, and participation guidelines in Enclosure 5.

For shareholders who wish to attend the meeting electronically or appoint a proxy (excluding the Company's independent directors), registration and proxy appointment can be completed via the AFF E Meeting system, following the procedures outlined in Enclosure 5, from April 14, 2025, until the conclusion of the meeting on April 28, 2025.

For shareholders who wish to appoint an independent director as their proxy, as listed in Enclosure 3, they may grant proxy authorization through the AFF E Meeting system, following the procedures outlined in Enclosure 5. Alternatively, shareholders may submit the proxy authorization documents via registered postal mail to the Investor Relations Department, Bangkok Genomics Innovation Public Company Limited, 3689 Rama IV Road, Phra Khanong, Khlong Toei, 10110, from April 14, 2025, to April 25, 2025. The proxy documents sent by mail must be received by the Company no later than April 25, 2025.

Details regarding the required documents and evidence for registration via the AFF E Meeting system, supporting documents for proxy authorization, and voting procedures during the shareholders' meeting are provided in Enclosure 7.

Once the Company has verified the registration and submitted documents, as well as confirmed the shareholder list as of the Record Date (March 14, 2025), Affinity Relation Co., Ltd., the certified electronic meeting service provider, will send a link to access the electronic shareholders' meeting platform to shareholders via the email address provided during registration.

The Company recommends using Proxy Form B (as detailed in Enclosure 7), which allows shareholders to clearly specify their voting instructions. The meeting will be conducted in accordance with the Company's Articles of Association, as outlined in Enclosure 2.

On the date of the Meeting, shareholders or appointed proxies should join the meeting using the link provided via email during registration. The electronic meeting system will open for registration on April 28, 2025, from 08:30 AM onward, and the meeting will commence at 10:30 AM.

To support environmental sustainability, the Company has provided the 2024 Annual Report (Form 56-1 One Report) in QR Code format, as detailed in Enclosure 8.

Your faithfully,

- Saowalak Dansakul -

(Ms.Saowalak Dansakul)
Chief Executive Officer